Wolverine Asset Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-18,239
| Closed | -$21 | – | 1908 |
|
|
2024
Q2 | $21 | Buy |
18,239
+8,410
| +86% | +$290 | ﹤0.01% | 1647 |
|
|
2024
Q1 | $1.33K | Sell |
9,829
-7,816
| -44% | -$1K | ﹤0.01% | 1498 |
|
|
2023
Q4 | $2.6K | Sell |
17,645
-1,017
| -5% | -$136 | ﹤0.01% | 1536 |
|
|
2023
Q3 | $1.42K | Buy |
18,662
+5,290
| +40% | +$745 | ﹤0.01% | 1677 |
|
|
2023
Q2 | $2.32K | Sell |
13,372
-1,046
| -7% | -$167 | ﹤0.01% | 1564 |
|
|
2023
Q1 | $1.86K | Sell |
14,418
-1,127
| -7% | -$179 | ﹤0.01% | 1662 |
|
|
2022
Q4 | $2.54K | Buy |
15,545
+3,190
| +26% | +$444 | ﹤0.01% | 1846 |
|
|
2022
Q3 | $2K | Sell |
12,355
-5,874
| -32% | -$918 | ﹤0.01% | 2273 |
|
|
2022
Q2 | $4K | Sell |
18,229
-16,067
| -47% | -$4.35K | ﹤0.01% | 2157 |
|
|
2022
Q1 | $14K | Sell |
34,296
-14,476
| -30% | -$7.36K | ﹤0.01% | 1834 |
|
|
2021
Q4 | $42K | Sell |
48,772
-9,469
| -16% | -$11.9K | ﹤0.01% | 1559 |
|
|
2021
Q3 | $93K | Buy |
58,241
+56,377
| +3,025% | +$68.4K | ﹤0.01% | 1310 |
|
|
2021
Q2 | $1K | Buy |
+1,864
| New | +$1.51K | ﹤0.01% | 2130 |
|
Wolverine Asset Management's EFTRW Position: Q3 2024 in Review
Wolverine Asset Management sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 18,239 shares — an estimated $21 sold.
Wolverine Asset Management first reported a position in EFTRW in Q2 2021 and held it in 13 quarters. The position peaked at $93K in Q3 2021. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.
- Wolverine Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
- Wolverine Asset Management sold 18,239 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $21.
- Wolverine Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2021 and held it in 13 quarters.
- Wolverine Asset Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $93K in Q3 2021.
- 1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.
Based on Wolverine Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.